Exited position

Bill Gates’s Johnson & Johnson (JNJ) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Gates Foundation TrustVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ4 2003Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares2.52MHighest verified quarter-end share count
Quarters reported13Verified quarters with shares above zero
What happened?

Gates Foundation Trust first reported Johnson & Johnson in Q4 2003. The reported position was increased across later filings. The latest verified relationship event shows that Gates Foundation Trust sold the entire position in Q4 2023, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q4 2023
Sold the entire position−14.95K shares · No shares reported at quarter-end
Q3 2023
New position+14.95K shares · 14.95K shares reported
Filing context

Quarter-end price $155.75 · Estimated holding basis $155.75

Q3 2007
Bought 143.9% more+1.48M shares · 2.52M shares reported after the change
Filing context

Quarter-end price $65.70 · Estimated holding basis $64.03

Q1 2006
New position+1.03M shares · 1.03M shares reported
Filing context

Quarter-end price $59.22 · Estimated holding basis $60.10

Q2 2005
Sold the entire position−1.03M shares · No shares reported at quarter-end

5 unchanged quarters are collapsed by default.

Portfolio importance

How important was Johnson & Johnson in Gates Foundation Trust’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.0%Q3 2023
Last reported rank#54of 74 reported positions
Peak portfolio weight2.0%Q1 2005
Best historical rank#13Q3 2007
At peak importanceQ1 2005
JNJ
2.0%
Largest holding
17.0%
Cross-investor discovery

Who else owns Johnson & Johnson?

Also reported by 5 other tracked investors in their latest verified filings.

Ray DalioBridgewater Associates, LP
JNJ0.7% of reported portfolio
Joel GreenblattGotham Asset Management
JNJ0.1% of reported portfolio
George SorosSoros Fund Management
JNJ0.1% of reported portfolio
Explore Johnson & Johnson across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$269.992026-09-18

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

View Johnson & Johnson stock page →

This tracker follows the Gates Foundation Trust’s Form 13F disclosures. It is not Bill Gates’s personal brokerage account, and 13F filings do not reveal exact trade dates or execution prices.